Skip to main content
Log in

Principles of Pharmacoeconomic Analysis of Drug Therapy

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Economic analyses have become increasingly important in healthcare in general and with respect to pharmaceuticals in particular. If economic analyses are to play an important and useful role in the allocation of scarce healthcare resources, then such analyses must be performed properly and with care. This article outlines some of the basic principles of pharmacoeconomic analysis. Every analysis should have an explicitly stated perspective, which, unless otherwise justified, should be a societal perspective. Cost minimisation, cost-effectiveness, cost-utility and cost-benefit analyses are a family of techniques used in economic analyses. Cost minimisation analysis is appropriate when alternative therapies have identical outcomes, but differ in costs. Cost-effectiveness analysis is appropriate when alternative therapies differ in clinical effectiveness but can be examined from the same dimension of health outcome. Cost-utility analysis can be used when alternative therapies may be examined using multiple dimensions of health outcome, such as morbidity and mortality. Cost-benefit analysis requires the benefits of therapy to be described in monetary units and is not usually the technique of choice. The technique used in an analysis should be described and explicitly defended according to the problem being examined. For each technique, the method of determining costs is the same; direct, indirect, and intangible costs can be considered. The specific costs to be used depend on the analytical perspective; a societal perspective implies the use of both direct and indirect economic costs. A modelling framework such as a decision tree, influence diagram, Markov chain, or network simulation must be used to structure the analysis explicitly. Regardless of the choice of framework, all modelling assumptions should be described. The mechanism of data collection for model inputs must be detailed and defended. Models must undergo careful verification and validation procedures. Following baseline analysis of the model, further analyses should examine the role of uncertainty in model assumptions and data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Beck JR, Pauker SG. The Markov process in medical prognosis. Medical Decision Making 3(4): 411–458, 1983

    Article  Google Scholar 

  • Blades CA, Culyer AJ, Walker A. Health service efficiency: appraising the appraisers — a critical review of economic appraisal in practice. Social Science in Medicine 25(5): 461–472, 1987

    Article  CAS  Google Scholar 

  • Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics, Harvey Whitney Books Company, Ohio, 1991

    Google Scholar 

  • Clemen RT. Making Hard Decisions, PWS Kent, Boston, 1991

    Google Scholar 

  • Crane VS. Economic aspects of clinical decision making: applications of clinical decision analysis. American Journal of Hospital Pharmacy 45: 548–553, 1988

    PubMed  CAS  Google Scholar 

  • Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Medical Decision Making 6(2): 85–92, 1986

    Article  PubMed  CAS  Google Scholar 

  • Dao TD. Cost-benefit and cost-effectiveness analysis of drug therapy. American Journal of Hospital Pharmacy 42: 791–802, 1985

    PubMed  CAS  Google Scholar 

  • Dittus RS, Roberts SD, Wilson JR. Quantifying uncertainty in medical decisions. Journal of the American College of Cardiology 14(3): 23A–28A, 1989

    Article  PubMed  CAS  Google Scholar 

  • Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Medical Decision Making 5(2): 157–177, 1985

    Article  PubMed  CAS  Google Scholar 

  • Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term ‘cost-effective’ in medicine. New England Journal of Medicine 314(4): 253–256, 1986

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF. Principles of economic appraisal in health care, Oxford University Press, Oxford, 1980

    Google Scholar 

  • Drummond MF. Survey of cost-effectiveness and cost-benefit analyses in industrialised countries. World Health Statistical Quarterly 38(4): 383–401, 1985

    CAS  Google Scholar 

  • Drummond MF, Stoddard GL, Labelle R, Cushman R. Health economics: An introduction for clinicians. Annals of Internal Medicine 107(1): 88–92, 1987a

    PubMed  CAS  Google Scholar 

  • Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes, Oxford Medical Publications, Oxford, New York, Toronto, 1987b

    Google Scholar 

  • Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. Journal of the American Medical Association 262(2): 2879–2886, 1989

    Article  PubMed  CAS  Google Scholar 

  • Eisenhut RD, Dittus RS, Roberts SD, Wilson JR. Comparing averaged-out utilities of probability trees having random parameters. Society for Industrial and Applied Mathematics Journal of Scientific and Statistical Computing 12(5): 1140–1161, 1991

    Google Scholar 

  • Evans D, Freund D, Dittus R, Robertson J, Henry D. The use of economic analysis as a basis for inclusion of pharmaceutical products on the Pharmaceutical Benefits Scheme, Commonwealth of Australia, Department of Health, Housing, and Community Services, Canberra, Australia, 1990

    Google Scholar 

  • Feller W. An introduction to probability theory and its applications, John Wiley & Sons, New York, 1968

    Google Scholar 

  • Froberg DG, Kane RL. Methodology for measuring health-state preferences. III. Population and context effects. Journal of Clinical Epidemiology 42(6): 585–592, 1989

    Article  PubMed  CAS  Google Scholar 

  • Gafni A. The quality of QALYs: do QALYs measure what they at least intend to measure? Health Policy 13(1): 81–85, 1989

    Article  PubMed  CAS  Google Scholar 

  • Gagnon JP, Osterhaus P. Proposed drug-drug cost effectiveness methodology. Drug Intelligence and Clinical Pharmacology 21: 211–216, 1987

    CAS  Google Scholar 

  • Gramlich EM. Benefit-cost analysis of government programs, Prentice Hall, Englewood Cliffs, 1981 Guyatt G, Drummond M, Feeny D, Tugwell P, Stoddart GL, et al. Guidelines for the clinical and economic evaluation of health care technologies. Social Science and Medicine 22(4): 393–408, 1986

    Article  Google Scholar 

  • Henry D. Economic analysis as an aid to subsidisation decisions: the development of the Australian guideline for pharmaceuticals. Pharmacoeconomics 1(1): 54–67, 1992

    Article  PubMed  CAS  Google Scholar 

  • Hill WL. Economic evaluation of pharmacologic therapy. Drug Intelligence and Clinical Pharmacology 20: 594–596, 1986

    CAS  Google Scholar 

  • Hillier FS, Lieberman GJ. Introduction to operations research, Holden-Day, San Francisco, 1974

    Google Scholar 

  • Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Hillman BJ, Kahan JP, Neu R, Hammons GT. Clinical trials to evaluate cost-effectiveness. Investigational Radiology 24(2): 167–171, 1989

    Article  CAS  Google Scholar 

  • Howard RA, Matheson JE. The principles and applications of decision analysis, Strategic Decisions Group, Menlo Park, 1984

    Google Scholar 

  • Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychology 1(1): 61–80, 1982

    Article  Google Scholar 

  • Kats BP, Hui SL. Variance estimation for medical decision analysis. Statistics in Medicine 8(2): 229–241, 1989

    Article  Google Scholar 

  • Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value tradeoffs, Wiley, New York, 1976

    Google Scholar 

  • Klein RW, Dittus RS, Roberts SD. Simulation modeling and health care decision-making: an annotated bibliography, Regenstrief Institute for Health Care, Indianapolis, 1991

    Google Scholar 

  • Law AM, Kelton WD. Simulation modeling and analysis, McGraw-Hill, New York, 1991

    Google Scholar 

  • Lohr K (Ed.) Advances in health status assessment. Medical Care 27(3): S1–S293, 1989

    Google Scholar 

  • Mehres A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalent. Medical Decision Making 9(2): 142–149, 1989

    Article  Google Scholar 

  • Oster G. Economic aspects of clinical decision making: applications in patient care. American Journal of Hospital Pharmacy 45: 543–547, 1988

    PubMed  CAS  Google Scholar 

  • Parsen E. Stochastic processes, Holden-Day, New York, 1962

    Google Scholar 

  • Raiffa H. Decision analysis: introductory lectures on choices under uncertainty. Addison-Wesley, Reading, 1968

    Google Scholar 

  • Roberts SD, England WL. Survey of the application of simulation to health care. Simulation Series 10 (1), Society for Computer Simulation, La Jolla, 1981

    Google Scholar 

  • Roberts SD, Klein RW. Simulation of medical decisions: applications of SLN. Simulation 43(5): 234–241, 1984

    Article  Google Scholar 

  • Shepard DS, Thompson M. First principles of cost-effectiveness analysis in health. Public Health Reports 94(6): 535–543, 1979

    PubMed  CAS  Google Scholar 

  • Simpson CA, Souney PF. Calculating costs of drug therapy: a review of a decade of literature (1977–1987). Clinical Therapeutics 10(6): 616–650, 1988

    PubMed  CAS  Google Scholar 

  • Sox HC, Blatt MA, Higgins MC, Marton KI. Medical decision making, Butterworth Publishers, Boston, London, Durban, Singapore, Sydney, Toronto, Wellington, 1988

    Google Scholar 

  • Stokey E, Sechauser R. A primer for policy analysis, Norton, New York, 1978

    Google Scholar 

  • Torrance GW. Toward a utility theory foundation for health status index models. Health Services Research 11(4): 349–69, 1976

    PubMed  CAS  Google Scholar 

  • Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programmes. Health Services Research 7(2): 118–133, 1972

    PubMed  CAS  Google Scholar 

  • von Neumann J, Morgenstern O. Theory of games and economic behavior, John Wiley, New York, 1953

    Google Scholar 

  • Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care, Health Administration Press, Ann Arbor, 1982

    Google Scholar 

  • Weinstein MC. Economic assessment of medical practices and technologies. Medical Decision Making 1(4): 309–330, 1981

    Article  PubMed  CAS  Google Scholar 

  • Weinstein MC, Fineberg HV. Clinical decision analysis, W.B. Saunders Company, Philadelphia, London, Toronto, 1980

    Google Scholar 

  • Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 296(13): 716–721, 1977

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freund, D.A., Dittus, R.S. Principles of Pharmacoeconomic Analysis of Drug Therapy. Pharmacoeconomics 1, 20–29 (1992). https://doi.org/10.2165/00019053-199201010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199201010-00006

Keywords

Navigation